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occurs more likely in CKD patient as compared with non-CKD patients, with consistent hazard ratios, up to 6.5. 3 With this background, in the 1st generation drug eluting stents (DES) era, following the general ST warning with DES, the European Society of Cardiology (ESC) Guidelines for myocardial revascularization (2010), discouraged the systematic use of DES CKD patients. 4 This statement was then mitigated by the following release of ESC Guidelines in 2014, 5 when the use of 2nd generation took over 1st generation DES. However, the evidence to support this shift of recommendation, was coming mostly from retrospective registries 6, 7 and by a confident generalization in CKD patients of data which favor of 2nd generation DES in the overall population. No specific recommendations in this subset of patients are provided by American Heart/College guidelines.
Importantly, CKD patients, are systematically excluded or underincluded by randomized controlled trials (RCT), therefore the evidence to guide stent type implantation in these specific population is scarce, albeit needed.
We reported, in a cohort of CKD patients out of the PRODIGY study, that 2nd generation, limus-based DES, should be favored over 1st
generation paclitaxel-based DES or bare-metal stents (BMS) to reduce ST and improve outcome. 8 The objective of this manuscript is to perform a systematic review of all the evidence available in CKD patients undergoing
PCI and to meta-analyze clinical outcome according to stent type (BMS vs DES). For this purpose, primary outcome was all-cause mortality. We also collected the following secondary outcome: composite of all-cause mortality and recurrent myocardial infarction (MI); cardiovascular mortality; stent-related complications such as ST and TVR/TLR; we also include direct and indirect comparisons of clinical outcome between 1st generation DES, 2nd generation DES and BMS in a network meta-analysis design.
2 | METHODS
| Study outcome and eligibility criteria
We searched articles including both stent-related outcome and long term clinical events in patients with CKD, defined by eGFR < 60 mL/min (either Cockroft-Gault or MDRD formula), studies including only patients on permanent haemodialysis were excluded.
Eligibility criteria are summarized in Table S1 . Research strategies and keywords are outlined in supplementary Table S2 . Also, additional articles were retrieved from the reference lists and a citation analysis was performed to identify newer studies that had cited older ones. The librarian (VS) examined titles and abstracts and classified them as "to be included,"
"to be excluded," and "to be decided upon," based on the eligibility criteria and the keywords used. Two junior interventional Cardiologists (VG and VG) reviewed full text articles independently to check eligibility criteria. Final decision to include was made by consensus between an experienced Interventional Cardiologist (GC) and a Biostatisticians (CK).
| Systematic review
Articles full text were retrieved. Reasons for non-inclusion were 
| Statistical analysis
The PRISMA and MOOSE guidelines for meta-analysis, as well as the Cochrane manual, were used. The review included retrospective studies with unadjusted estimates of the relative risk (RR), adjusted by multivariable regression or propensity score analysis, and RCTs.
Primary outcome was the incidence of all-cause death; among secondary outcome, we included: the composite endpoint of death and MI, MI alone, ST, TLR, or TVR and death for cardiovascular cause.
Outcome of interest were compared using a person-year approach between patients receiving BMS or DES in the meta-analysis and between patients receiving 1st generation DES, 2nd generation DES and BMS in the network meta-analysis. Patient characteristics were summarized over studies with the median and 25th-75th percentiles.
Within each study, the adjusted relative risk (RR) with its 95%CI for each categorical outcome, was retrieved from the articles. For the analysis of the secondary populations the RR was either retrieved from the articles or calculated from the available data. Finally, study RRs were then pooled according to the DerSimonian and Laird random effects models. Statistical heterogeneity was evaluated by the Cochran Q test and measured by the I-squared statistic. The meta-analytic estimates were computed both by design and overall. The following study designs were considered: registries, cohort studies with propensity score matching, post-hoc RCT and RCT. Two sensitivity analyses on outcome of interest were performed: a "leave-one-out" meta-analysis to confirm that no study had a major influence on the overall estimate and a meta-regression to confirm that no study/ patient characteristic had a major influence on the overall estimate.
The following potential confounders were assessed: prevalence of patients on dialysis, gender, age, diabetes, eGFR, acute coronary syndrome and, total stent length. 
| Study design and population
The final population included 376 169 patients of which 76 557 patients with CKD who received BMS (35 807) or DES (37 650 1st generation and 3100 2nd generation DES). Patients characteristics were well matched between the groups as it is shown in Table 2 , we only found a higher prevalence of patients in permanent haemodialysis in the DES group as compared to patients receiving BMS. Median Table 3 and shown in Figure 2 . A detailed report of different MI definitions as reported by each study is provided in supplementary Table S4 .
| Primary outcome
Patient receiving DES had a significant 18% lower incidence of allcause mortality (95% confidence interval 6% to 29% lower in DES) compared to patients receiving BMS as it is shown in Figure 3 .
| Secondary outcome
The composite of death or MI was significantly reduced in DES patients (random effect, RR 0.78, 95%CI 0.67-0.91), as it is shown in Importantly, we did not find any evidence of publication bias (data not shown).
| Outcome and network meta-analysis
Results from the network meta-analysis design are summarized in Table 3 . These results confirmed a lower incidence of all cause death, 
| Sensitivity analyses
The "leave-one-out" analysis confirmed that no study had a major influence on the overall estimate of clinical outcome. Similarly, the meta-regression We found no effect of male or acute coronary syndrome prevalence on allcause death as on other explore outcomes. CKD patients associated with higher atherosclerotic burden, diffuse coronary disease, and calcification which may also be associated to sub-optimal mechanical stent result as malaposition, 
| LIMITATIONS
Studied including CKD patients in permanent haemodialysis and after kidney transplantation are excluded from our meta-analysis. Specifically, haemodialysis define end-stage CKD patients with severe metabolic impairment and altered drug kinetics which may also impact outcome, therefore the reason to exclude these patients, is to focus on the most homogeneous and prevalent CKD population.
The studies included used different MI definitions, this may partly explain heterogeneity across the studies and should be considered for generalizations, a detailed outline of MI defintions is shown in supplementary Table S4 .
We may not exclude a time bias to explain superiority of 2nd gen DES over 1st gen DES, especially on indirect comparisons, as trials comparing 2nd gen DES are more contemporary, with improved medical facilities, medical treatments, use of new antiplatelet agents, and interventional strategies. However direct and indirect effect are consistent as reported in Table 3 .
CKD patients with stable or acute coronary syndrome often present with multivessel disease, in this clinical setting, international guidelines recommend to consider myocardial revascularization with coronary artery bypass grafting rather than PCI. We acknowledge that CABG treated CKD patient are not included for comparison in the present meta-analysis.
| CONCLUSIONS
The use of DES in CKD patients undergoing PCI is superior to BMS in reducing major adverse clinical events such as all-cause mortality and the composite of death or MI. This is supported and possibly explained, by a lower risk of stent-related events such as ST and TVR/TLR.
Second generation DES may further reduce clinical events as compared to 1st generation DES and should be considered the first choice in CKD patients with indication to PCI.
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